Ignite Creation Date:
2025-12-25 @ 2:40 AM
Ignite Modification Date:
2026-03-01 @ 12:04 PM
Study NCT ID:
NCT01997333
Status:
COMPLETED
Last Update Posted:
2019-03-08
First Post:
2013-11-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Sponsor:
Celldex Therapeutics
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic gpNMB Over-expressing Triple Negative Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Metastatic Breast Cancer | View |
| None | Locally advanced breast cancer | View |
| None | Breast cancer | View |
| None | Triple negative | View |
| None | Estrogen | View |
| None | Progesterone | View |
| None | HER2 receptors | View |
| None | Targeted treatment for breast cancer | View |
| None | Antibody-drug-conjugate | View |
| None | Breast Neoplasms | View |
| None | CDX-011 | View |
| None | gpNMB | View |
| None | METRIC | View |
| None | Glembatumumab vedotin | View |
| None | Triple Negative Breast Cancer | View |
| None | TNBC | View |